Some experts fear that the approval of lecanemab, a drug that reduced the rate of cognitive decline among participants of a clinical trial, may cause drug companies to neglect other more fruitful treatment approaches.
the drug to Alzheimer’s patients. Due to the controversy surrounding the drug’s efficacy and its high price, as well as the negative publicity it has received, few patients have received it. As a result, many doctors who treat the disease have been left, once again, with limited options.
cause the loss of brain cells that leads to cognitive decline in people who suffer from Alzheimer’s. By reducing the amount of amyloid plaques in the brain, these treatments are believed to help slow the process of memory loss and cognitive decline. He said the accelerated FDA approval of lecanemab made sense because in clinical trials the drug showed that it can affect a biomarker associated with a disease. In this case, that biomarker is the reduction of beta-amyloid in the brain. “Lecanemab definitely removes amyloid plaques,” Greicius said.
The new drug, which is administered through intravenous infusions every two weeks, is costly. The companies that develop it have said it will be priced at $26,500 per year. So far, the Centers for Medicare and Medicaid Services has, and unless lecanemab receives full FDA approval, that isn’t likely to change.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘The Eternal Memory’ Review: A Moving Chronicle of a Marriage Challenged by Alzheimer’sOscar-nominated director Maite Alberdi builds an intimate collaboration with a woman bravely struggling to keep her husband’s brilliant mind functioning.
Read more »
FDA clears Wandercraft's exoskeleton for stroke patient rehab | EngadgetWandercraft's exoskeleton has received FDA clearance to help stroke patients recover their gait..
Read more »
Alleviating Symptoms: Brain Stimulation Could Help Treat Alzheimer’s DiseaseResearchers at Charité have uncovered a brain network that, when stimulated, can alleviate symptoms. Alzheimer's disease, which is the most common form of dementia, is challenging to treat. A possible therapy is deep brain stimulation delivered by a pacemaker-like device. A team of researchers from
Read more »
Hersey claims 2nd straight MSL crown; Warren rules Lake County meetHersey entered the second day of the MSL Conference Wrestling Tournament with a narrow 3.5-point lead over Prospect ahead of the action at William Perry Gymnasium.
Read more »